Laino Medical and Medtronic signed a strategic cooperation agreement

At the Medtronic Medical Innovation Accelerator located in Pujiang Town, Shanghai, Laino Medical, a domestic otolaryngology diagnostic and treatment equipment R&D and manufacturing company, signed a strategic cooperation agreement with Medtronic, a global leader in medical technology, services and solutions. Laino Medical has settled in Medtronic Medical Innovation Accelerator, the two parties will cooperate on local innovation in the field of medical devices.

Shanghai, June 21, 2021 -- At the Medtronic Medical Innovation Accelerator in Pujiang Town, Shanghai, Laino Medical, a domestic otolaryngology diagnostic and treatment device R&D and manufacturing company, signed a strategic cooperation with Medtronic, a global leader in medical technology, services and solutions. According to the agreement, Laino Medical will enter the Medtronic Medical Innovation Accelerator. The two parties will cooperate on local innovation in the field of medical devices, work together to build local R&D capabilities, and strive to provide high-quality clinical services to domestic patients and promote the improvement of China's medical technology level.

Laino Medical and Medtronic signed a strategic cooperation agreement. Both parties will continue to cooperate on local innovation.

Medtronic Global Senior Vice President and Greater China President Gu Yushao, Greater China Vice President Rob Sandfelder, Greater China R&D Center Vice President Dr. Peng Yang, as well as Laino Medical Chairman and General Manager Cui Teng, Laino Medical General Manager Wang Dijun , Li Zheng, deputy general manager of Laino Mechuang, and others attended the signing ceremony.

Laino Medical and Medtronic signed a strategic cooperation agreement. Both parties will continue to cooperate on local innovation.

Laino Medical settled in Zhangjiang Medical Valley, Pudong New Area, Shanghai in 2015. It occupies a leading position in the domestic otolaryngology diagnosis and treatment market. It has the most extensive sales channels for otolaryngology medical products in the country and provides a variety of otolaryngology doctors and patients. Product selection, and based on becoming a provider of overall solutions and multiple technology platforms in the field of otolaryngology.Laino Medical is also the first innovative medical device company invested by Medtronic China Fund. In 2016, Medtronic's US dollar and RMB funds jointly invested in Laino Medical, and additional investment was made in 2018, further helping Laino become China's number one local ENT company. Diagnosis and treatment platform company.This time, Leno signed up to stay at the Medtronic Medical Innovation Accelerator, opening up in-depth cooperation between the two parties in local innovation.

Laino Medical and Medtronic signed a strategic cooperation agreement. Both parties will continue to cooperate on local innovation.

Medtronic is one of the world's largest medical device companies and one of the Fortune 500 companies, providing medical technology, services and solutions globally.The Medtronic Medical Innovation Accelerator was established in Shanghai in 2019. It is committed to empowering early-stage medical technology startups with product transformation potential, helping to achieve innovation maturity and achievement transformation from the laboratory to the market, and create innovation by serving patients and improving industry capabilities. value.

Cui Teng, chairman and general manager of Laino Medical, said: 'We are very honored to cooperate with Medtronic, a global leader in medical technology, in local innovation. Medtronic's valuable experience and knowledge accumulation will accelerate the technological improvement of Laino Medical. , helping us better serve doctors and patients in the field of otolaryngology.'

Mr. Gu Yushao, President of Medtronic China, said: 'Participating in the growth of Leno allows Medtronic to experience the growth rate of local innovative companies. Medtronic looks forward to cooperating with more local medical device companies like Leno to explore potential external innovation opportunities. Build local R&D capabilities, promote the integration of China's medical technology level with international standards, and better empower the innovation of cutting-edge therapies in the Chinese market.'

About Nanos Medical (http://www.nanosmedical.com)

Laino Medical is the leader in overall otolaryngology diagnosis and treatment solutions in China. It serves 30,000 otolaryngology professional medical staff and is committed to promoting 12 advanced minimally invasive surgical technologies. The diagnosis and treatment items and clinical procedures provided can benefit 300 million people. A large number of otolaryngology patients.

Laino Medical Technology (Shanghai) Co., Ltd. was established in Zhangjiang Medical Valley, Pudong New Area, Shanghai in August 2015. In 2017, it established a R&D and production base for high-value consumables in the Medical Device Industrial Park of Suzhou High-tech Zone. In 2019, Laino Medical Reorganized with Chengdu Meichuang Medical, the leading domestic medical plasma technology platform.So far, Laino Medical has occupied a leading position in the domestic otolaryngology diagnosis and treatment market, and has contributed to the construction of more than thousands of otolaryngology and head and neck surgery medical institutions at home and abroad.

About Medtronic (www.medtronic.com)

Medtronic is a global leader in medical technology, services and solutions. Its business has spread to more than 150 countries and regions around the world and expanded to more than 70 disease areas, covering cardiovascular, surgical business, neuroscience and diabetes.Medtronic uses medical technology to help patients around the world 'relieve pain, restore health, and extend life.'

Medtronic Innovation Accelerator is an innovation incubation and acceleration platform established by Medtronic in Shanghai, China. Its purpose is to promote the transformation of more medical technologies into valuable medical products and services in the Chinese market, and to become efficient health solutions that can be selected by patients. At the same time, it will create sustainable development capabilities for China to promote the construction of a global science and technology innovation center.